Abnova | Balance Sheet

Fiscal year is January-December. All values TWD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
492
504
298
232
188
145
Total Accounts Receivable
62
59
64
68
106
89
Inventories
586
611
597
581
568
495
Other Current Assets
5
4
3
5
9
7
Total Current Assets
1,145
1,178
962
886
870
736
Net Property, Plant & Equipment
50
44
173
226
293
343
Total Investments and Advances
-
-
-
19
28
43
Intangible Assets
38
31
34
35
25
63
Other Assets
10
6
19
11
7
6
Total Assets
1,285
1,308
1,249
1,248
1,304
1,295
ST Debt & Current Portion LT Debt
-
-
1
1
1
Accounts Payable
13
19
19
14
14
Income Tax Payable
-
-
16
6
15
Other Current Liabilities
43
59
46
49
47
Total Current Liabilities
55
78
82
71
78
Deferred Taxes
41
50
61
70
80
Other Liabilities
-
-
-
-
1
Total Liabilities
55
78
82
72
79
Common Equity (Total)
1,230
1,230
1,167
1,176
1,225
Total Shareholders' Equity
1,230
1,230
1,167
1,176
1,225
Total Equity
1,230
1,230
1,167
1,176
1,225
Liabilities & Shareholders' Equity
1,285
1,308
1,249
1,248
1,304

About Abnova

View Profile
Address
108 Jhouzih Street
Taipei TP 114
Taiwan
Employees -
Website http://www.abnova.com.tw
Updated 07/08/2019
Abnova Taiwan Corp. is engaged in researching, developing, manufacturing and selling antibodies. It also supplies medicines and human genes albumen. Its products include antibodies for virus, microbial, neuroscience and others.